Yantai University

DULLES, Va., Jan. 17, 2023 /PRNewswire/ -- SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, will be supporting, through companion diagnostic [68Ga]FAPI-46 PET, Yantai LNC Biotechnology's recently FDA accepted clinical study. On Jan 6th, 2023 Yantai LNC Biotechnology received FDA clearance to proceed with a Phase 1 clinical study of 177Lu-LNC1004 injection, targeting fibroblast activation protein (FAP). The study accepted as part of the FDA IND review is a Phase I, open label study of the safety and dosimetry of a 4-dose regimen of escalating doses of 177Lu-LNC1004 injection in adult patients with advanced FAP-positive solid tumors. As the companion diagnostic agent of 177Lu-LNC1004 Injection, [68Ga]FAPI-46 PET will be used to screen subjects and assess therapeutic effect. Yantai obtained access to [68Ga]FAPI-46 through a letter of cross reference to SOFIE Biosciences' IND along with corresponding precursor and reference standard for use. Prof. Xiaoyuan (Shawn) Chen, co-founder of Yantai LNC Biotechnology and editor-in-chief of the journal Theranostics, stated, "we appreciate the opportunity to work closely with SOFIE in pushing the long-acting FAPI formula 177Lu-LNC1004 forward. Applying Evans blue derivatives to modify pharmacokinetics and pharmacodynamics is a platform technology Yantai LNC Biotechnology has successfully implemented to multiple radioligands such as FAP inhibitors." Sherly Mosessian, Ph.D., SOFIE's Chief Scientific Officer, added, "as license holders of FAPI family of compounds for diagnostic and companion diagnostic use, we are excited to support this very promising study by having [68Ga]FAPI-46 serve as a companion diagnostic tool for patient selection and treatment monitoring with 177Lu-LNC1004. This highlights the power of theranostics in utilizing the same target, FAP, for imaging and treatment interventions." The study is expected to enroll up to 24 subjects in advanced solid tumors that show high level of FAP expression detected by [68Ga]FAPI-46 and will establish the recommended expansion phase dose with 177Lu-LNC1004. Site feasibility and selection is complete and the study is expected to launch in Singapore Q2 2023. About Yantai LNC Biotechnology Yantai LNC Biotechnology Singapore Pte. Ltd. is a wholly owned subsidiary of Yantai Dongcheng Pharmaceutical Group. As the unique innovative nuclear medicine development platform in Dongcheng Group, Yantai LNC Biotech is committed to radionuclide diagnosis and therapy innovation. For more information, contact [email protected]. About 177Lu-LNC1004 177Lu-LNC1004 is a fibroblast activation protein inhibitor (FAPI) modified with Evans blue (EB) and a metal chelator (DOTA), radiolabeled with beta-emitting radionuclide lutetium Lu-177. As a first-in-class drug the FAP-targeting probe will be used to treat adult patients with advanced FAP-positive solid tumors. About FAPI Fibroblast Activation Protein (FAP) is highly expressed in cancer associated fibroblasts (CAF) across several tumor entities. Developed by the team at the Heidelberg University Hospital (UKHD), quinoline-based PET tracers that act as FAP inhibitors (FAPI) have shown encouraging results in pre-clinical and clinical studies. SOFIE has licensed the rights for diagnostic and companion diagnostic use of FAPI family of compounds from Heidelberg University. [68Ga]FAPI-46 is the lead gallium-68 and [18F]FAPI-74 is the lead fluorine-18 radiolabeled PET tracer of FAPI family of compounds. They have demonstrated favorable dosimetry, avidity, safety and biodistribution profile amenable for detection of FAP-expressing cells in patients with various cancers. Both products have active INDs for Phase 2 studies in cancers of the digestive system. About SOFIE SOFIE's vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (theranostics). With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value theranostic intellectual property, SOFIE is poised to deliver on the promise of radiopharmaceuticals. For more information, contact [email protected]. SOURCE SOFIE

Dublin, March 22, 2021 (GLOBE NEWSWIRE) -- The "Synthetic Leather (Artificial Leather) Market by Type (Polyurethane, Polyvinyl Chloride, Bio-based), End-Use Industry (Footwear, Furnishing, Automotive, Clothing, Bags, Purses & Wallets, Sports, Electronics) and Region - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering. The synthetic leather market size is estimated to be USD 63.3 billion in 2020 and is projected to reach USD 78.5 billion by 2025, at a CAGR of 4.4% between 2020 and 2025. Factors such as growing demand from footwear industry, no animal killing involved, advantages over pure leather, and increasing demand for luxury cars and electric vehicles will drive the synthetic leather market. The major restraint for the market will be harmful effects of PU and PVC on humans and substitute for synthetic leather in the automotive industry. However, focus on development of bio-based synthetic leather will act as an opportunity for the market. PU-based leather is the largest type for synthetic leather market in 2019 PU-based leather is generally made using PU and different fabrics. It is made by coating a fabric such as polyester or cotton with a flexible polymer. It is further treated by various processes to look like animal hide-based leather. PU-based synthetic leather is made by using soft polymers, hence does not require additional plasticizers. It offers various advantages such as waterproof, lightweight, and softness. In some cases, PU-based leather may tear easily, but does not fade or crack in sunlight. It is widely preferred in the automotive and clothing industries. PU-based leather is considered more environment-friendly than vinyl-based leather, as it does not create dioxins. PU-based leather is more expensive than PVC-based leather due to its extensive manufacturing process. Footwear is estimated to be the largest end-use industry in synthetic leather market between 2020 and 2025. Synthetic leather is widely used in the footwear industry due to its excellent properties and high durability. It is used in shoe linings, shoe uppers, and insoles to make different types of footwear such as sports shoes, shoes & boots, and sandals & slippers. The increasing demand for footwear in developed and emerging countries is expected to drive the demand for synthetic leather. Synthetic leather is widely used to manufacture sports shoes for various games around the world due to its cost-effectiveness. Sports shoes made from synthetic leather look similar to those of pure leather and are offer various other properties such as resistance to water, heat, and rigid climatic conditions. It is used to make formal men's and women's footwear for official purposes, boots for women and men in the fashion industry, and for those living in the cold regions around the world. Boots made out of real leather tear when exposed to snow and water, but synthetic leather offers excellent resistance to water and snow. APAC is expected to be the largest synthetic leather market during the forecast period, in terms of value and volume. The APAC comprises major emerging nations such as China and India. Hence, the scope for the development of most industries is high in this region. The synthetic leather industry is growing significantly and offers opportunities for various manufacturers. The APAC region constitutes approximately 61.0% of the world's population, and the manufacturing and processing sectors are growing rapidly in the region. The APAC is the largest synthetic leather market with China being the major market which is expected to grow significantly. The rising disposable incomes and rising standards of living in emerging economies in the APAC are the major drivers for this market. The increasing population in the region accompanied with development of new technologies and products are projected to make this region an ideal destination for the growth of the synthetic leather industry. However, establishing new plants, implementing new technologies, and creating a value supply chain between raw material providers and manufacturing industries in the emerging regions of the APAC are expected to be a challenge for industry players as there is low urbanization and industrialization. Booming footwear and automotive sectors and advances in process manufacturing are some of the key drivers for the market in the APAC. Countries such as India, Indonesia, and China are expected to witness high growth in the synthetic leather market due to the increasing demand from the automotive industry. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights4.1 Attractive Market Opportunities for Synthetic Leather Manufacturers4.2 Rapid Growth in Synthetic Leather Market due to High Demand in Developing Regions4.3 Pu-Based Synthetic Leather Dominates Synthetic Leather Market4.4 Footwear & Furnishing Industry is the Potential Market for Synthetic Leather Manufacturers 5 Market Overview5.1 Introduction5.2 Market Segmentation5.2.1 Synthetic Leather Market Segmentation, by Type5.2.2 Synthetic Leather Market Segmentation, by End-Use Industry5.3 Market Dynamics5.3.1 Drivers5.3.1.1 Growing Demand from the Footwear Industry5.3.1.2 No Involvement of Animal Killing, Which Makes It a Major Alternative of Pure Leather5.3.1.3 Advantages Over Pure Leather5.3.2 Restraints5.3.2.1 Harmful Effects of Pu and Pvc5.3.3 Opportunities5.3.3.1 Focus on Development of Bio-Based Synthetic Leather5.4 Revenue Pocket Matrix5.4.1 Revenue Pocket Matrix for Synthetic Leather, by End-Use Industry5.5 Supply Chain Analysis5.6 Porter's Five Forces Analysis5.6.1 Bargaining Power of Suppliers5.6.2 Bargaining Power of Buyers5.6.3 Threat of Substitutes5.6.4 Threat of New Entrants5.6.5 Intensity of Competitive Rivalry5.7 Economic Indicators5.7.1 Industry Outlook5.7.1.1 Automotive5.7.1.2 Footwear 6 Synthetic Leather Market, by Type6.1 Introduction6.2 Pu Synthetic Leather6.2.1 Microfiber Leather6.3 Pvc-Based Synthetic Leather6.4 Bio-Based Leather 7 Synthetic Leather Market, by End-Use Industry7.1 Introduction7.2 Footwear7.2.1 Sports Shoes7.2.2 Formal Shoes & Boots7.2.3 Sandals & Slippers7.3 Furnishing7.3.1 Chairs7.3.2 Sofas7.3.3 Bean Bags & Others7.4 Automotive7.4.1 Seats7.4.2 Steering Wheel Covers7.4.3 Door Trim, Knob, & Gear Bot Covers7.5 Clothing7.5.1 Jackets7.5.2 Belts7.5.3 Tops, Pants, and Others7.6 Bags, Purses, & Wallets7.6.1 Bags7.6.2 Purses7.6.3 Wallets7.7 Others 8 Regional Analysis8.1 Introduction8.2 Asia-Pacific8.2.1 China8.2.2 India8.2.3 Japan8.2.4 South Korea8.2.5 Taiwan8.2.6 Thailand8.2.7 Malaysia8.2.8 Indonesia8.3 Europe8.3.1 Germany8.3.2 Italy8.3.3 France8.3.4 U.K.8.3.5 Spain8.3.6 Russia8.3.7 Poland8.3.8 Sweden8.3.9 Portugal8.4 North America8.4.1 U.S.8.4.2 Mexico8.4.3 Canada8.5 South America8.5.1 Brazil8.5.2 Argentina8.6 Middle East & Africa8.6.1 The Middle East8.6.2 Africa 9 Competitive Landscape9.1 Competitive Benchmarking 10 Company Profiles10.1 Kuraray Co., Ltd.10.2 San Fang Chemical Industry Co., Ltd.10.3 Teijin Limited10.4 Mayur Uniquoters Limited10.5 Nan Ya Plastics Industrial Co., Ltd.10.6 Filwel Co. Ltd10.7 Zhejiang Hexin Industry Group Co., Ltd.10.8 Alfatex10.9 H.R. Polycoats Pvt. Ltd.10.10 Yantai Wanhua Synthetic Leather Group Co., Ltd.10.11 Additional Companies (Marvel Vinyls, Kolon Industries Inc., Toray Industries Inc., Anhui Material Technology Co., Ltd. Amway, Shandong Jinfeng Artificial Leather Co., Ltd., Limited, Arora Vinyl Pvt. Ltd., Zhejiang Yongfa Synthetic Leather Co., Ltd, and Others) 11 Appendix11.1 Discussion Guide11.2 Knowledge Store: The Subscription Portal11.3 Introducing Rt: Real Time Market Intelligence11.4 Available Customizations For more information about this report visit

Creat Group will attempt to restructure its $1.5M offer to acquire Biotest after U.S. regulators nixed the deal. November 11, 2017 Deals and Financings China’s Creat Group will attempt to restructure its $1.5 billion offer to acquire Biotest , a German blood plasma company, after US regulators nixed the deal; Valeant Pharma closed its $190 million sale of California-based Obagi Medical Products to a group that includes China Regenerative Medicine; Zhejiang Huahai Pharma acquired China rights to an immuno-oncology candidate discovered by Eutilex of South Korea in a $65 million agreement that included a $30 million investment in Eutilex; EOC Pharma Group of Shanghai, an oncology spin-out from China in-licensing company Eddingpharm, closed a $32 million B funding round; AnchorDx Corp of Guangzhou raised $28 million in a Series B round to develop precision oncology products using next-generation sequencing technology; Exicure, a Chicago developer of nucleic acid drugs, closed a $11.2 million funding led by Yantai-based Luye Pharma; Ark Biosciences of Shanghai partnered with the California Institute for Biomedical Research of La Jolla to develop novel therapies for COPD and other lung diseases; Company News Sweden’s Genovis signed a China distribution agreement with Shanghai Titan Scientific for its portfolio of enzymes that are used in making biologic drugs; Cellular Biomedicine held an official opening for its new Shanghai CAR-T manufacturing facility, located in Zhangjiang High-Tech Park. Stock Symbols: (DE: BIOG) (NYSE: VRX) (HK: 2186) (NSDQ: CBMG)